TrialLeukemia2018

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Anna B Halpern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.